Palo Alto Investors LP raised its holdings in shares of United Therapeutics Co. (NASDAQ:UTHR) by 1.0% during the 1st quarter, HoldingsChannel reports. The fund owned 1,622,631 shares of the biotechnology company’s stock after purchasing an additional 16,381 shares during the period. United Therapeutics accounts for approximately 7.8% of Palo Alto Investors LP’s portfolio, making the stock its 4th biggest holding. Palo Alto Investors LP’s holdings in United Therapeutics were worth $182,319,000 at the end of the most recent reporting period.
Other large investors have also added to or reduced their stakes in the company. Renaissance Technologies LLC grew its stake in shares of United Therapeutics by 14.9% in the 4th quarter. Renaissance Technologies LLC now owns 1,462,378 shares of the biotechnology company’s stock valued at $216,359,000 after buying an additional 189,378 shares in the last quarter. LSV Asset Management lifted its holdings in shares of United Therapeutics by 53.3% during the first quarter. LSV Asset Management now owns 420,340 shares of the biotechnology company’s stock worth $47,229,000 after buying an additional 146,194 shares during the last quarter. BlackRock Inc. lifted its holdings in shares of United Therapeutics by 3.0% during the first quarter. BlackRock Inc. now owns 4,912,985 shares of the biotechnology company’s stock worth $552,023,000 after buying an additional 141,416 shares during the last quarter. Mackay Shields LLC acquired a new position in shares of United Therapeutics during the first quarter worth approximately $14,199,000. Finally, Prudential Financial Inc. raised its stake in shares of United Therapeutics by 29.1% in the first quarter. Prudential Financial Inc. now owns 303,352 shares of the biotechnology company’s stock valued at $34,084,000 after purchasing an additional 68,460 shares in the last quarter. 99.24% of the stock is currently owned by institutional investors.
A number of analysts have weighed in on the company. BidaskClub upgraded United Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 16th. Barclays restated an “underweight” rating and set a $105.00 target price (down previously from $115.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Credit Suisse Group reiterated an “underperform” rating and issued a $115.00 price target (down previously from $120.00) on shares of United Therapeutics in a report on Thursday, February 22nd. Finally, ValuEngine cut United Therapeutics from a “buy” rating to a “hold” rating in a report on Tuesday, February 27th. Three equities research analysts have rated the stock with a sell rating, five have assigned a hold rating and three have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $134.00.
United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, May 2nd. The biotechnology company reported $5.57 earnings per share for the quarter, topping analysts’ consensus estimates of $3.62 by $1.95. United Therapeutics had a return on equity of 26.68% and a net margin of 27.74%. The business had revenue of $389.20 million for the quarter, compared to analyst estimates of $393.96 million. During the same quarter in the previous year, the company posted $3.61 EPS. United Therapeutics’s quarterly revenue was up 5.0% compared to the same quarter last year. research analysts forecast that United Therapeutics Co. will post 13.04 EPS for the current year.
In related news, CEO Martine A. Rothblatt sold 301 shares of the company’s stock in a transaction that occurred on Tuesday, March 20th. The stock was sold at an average price of $110.48, for a total transaction of $33,254.48. Following the transaction, the chief executive officer now directly owns 21,652 shares of the company’s stock, valued at approximately $2,392,112.96. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, CEO Martine A. Rothblatt sold 1,100 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was sold at an average price of $110.01, for a total value of $121,011.00. Following the transaction, the chief executive officer now directly owns 1,240 shares in the company, valued at $136,412.40. The disclosure for this sale can be found here. Insiders sold a total of 153,134 shares of company stock worth $17,152,504 over the last three months. 8.20% of the stock is owned by company insiders.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.